Session 2: CML management, Practicalities
Chair: Prof. Tim Hughes

• Molecular monitoring in CML
  (A/Prof Susan Branford)
• Allograft - still a role in CML?
  (A/Prof Agnes Yong)

Molecular monitoring in CML
A/Prof. Susan Branford - SA Pathology / Universities of Adelaide and South Australia

• Gold standards of monitoring CML
• Molecular monitoring for best patient outcomes
• Milestone molecular responses in the first 12 months
• Long-term molecular monitoring recommended for prediction of resistance
• Imatinib resistant BCR-ABL1 kinase domain mutations
• When to test for mutations
• Long-term molecular monitoring of responding patients important to monitor adherence
• Regular molecular monitoring recommended for optimal disease management
• Summary
• Q&A Session
  
  

Allograft - still a role in CML?

A/Prof. Agnes Yong - SAHMRI / University of Adelaide

• Allogeneic stem cell transplantation: the most successful immunotherapy in CML
• Survival after alloSCT
• EBMT score for alloSCT in CML
• Which CML patient needs transplant?
• AlloSCT for patients harboring T315I BCR-ABL mutated leukemias
• Clinical impact of pretransplant use of multiple TKI's on the outcome of alloSCT
• Economics and alloSCT in CML
• Outcomes of alloSCT in children and adolescents
• Which conditioning regime for alloSCT?
• Role of TKI's after transplant
• Long-term follow-up after transplant for CML
• Summary
• Q&A Session